Skip to main content
Top
Published in: Archives of Dermatological Research 6/2014

01-08-2014 | Review

Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy

Authors: Paola Queirolo, Francesco Marincola, Francesco Spagnolo

Published in: Archives of Dermatological Research | Issue 6/2014

Login to get access

Abstract

Despite surgical treatment of primary tumor, about 5–10 % of melanoma patients will eventually suffer from cutaneous or subcutaneous metastasis. The presence of skin metastases decreases patients’ quality of life. Their management is a challenge and depends on several variables such as size and number of the lesions, their location, the presence or absence of visceral metastasis. When possible, radical surgical resection is the best approach; if surgery is not expected to provide a reasonable functional outcome, alternative treatments must be considered. Several local and loco-regional treatments, such as electrochemotherapy and regional chemotherapy, are available for the management of melanoma skin metastasis. Even if high response rates have been observed in several clinical trials, their impact on survival is not clear. Efforts are being made to improve their efficacy and minimize toxicity. The combination of such treatments with immunotherapy could be a strategy to induce durable responses and improve survival. In fact, regionally treated patients do not have the immune suppression associated with most systemic treatments, which could compromise the efficacy of immunotherapy, and recent findings suggest that the inflammatory reactions following loco-regional cytotoxic treatments, such as electrochemotherapy, may enhance the activity of immunotherapeutic agents. In this manuscript, we review recent studies on electrochemotherapy and melanoma skin metastasis, and we comment about the role that combinations with immunotherapy may have based on the data provided by clinical trials and translational research.
Literature
1.
go back to reference Andersen MH, Gehl J, Reker S et al (2003) Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13(6):449–459PubMedCrossRef Andersen MH, Gehl J, Reker S et al (2003) Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13(6):449–459PubMedCrossRef
2.
3.
go back to reference Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15(8):2195–2205PubMedCrossRef Beasley GM, Petersen RP, Yoo J et al (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15(8):2195–2205PubMedCrossRef
4.
go back to reference Byrne CM, Thompson JF, Johnston H et al (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15(1):45–51PubMedCrossRef Byrne CM, Thompson JF, Johnston H et al (2005) Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 15(1):45–51PubMedCrossRef
5.
go back to reference Campana LG, Valpione S, Mocellin S et al (2012) Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 99(6):821–830PubMedCrossRef Campana LG, Valpione S, Mocellin S et al (2012) Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 99(6):821–830PubMedCrossRef
6.
go back to reference Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26(36):5896–5903PubMedCentralPubMed Daud AI, DeConti RC, Andrews S et al (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26(36):5896–5903PubMedCentralPubMed
7.
go back to reference Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB (2003) Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol Immunother 52(3):162–170PubMed Donepudi M, Jovasevic VM, Raychaudhuri P, Mokyr MB (2003) Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol Immunother 52(3):162–170PubMed
8.
go back to reference Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB (2001) Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol 166(11):6491–6499PubMedCrossRef Donepudi M, Raychaudhuri P, Bluestone JA, Mokyr MB (2001) Mechanism of melphalan-induced B7-1 gene expression in P815 tumor cells. J Immunol 166(11):6491–6499PubMedCrossRef
9.
go back to reference Fisher R, Larkin J (2012) Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 4:243–252PubMedCentralPubMed Fisher R, Larkin J (2012) Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Manag Res 4:243–252PubMedCentralPubMed
10.
go back to reference Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 10(3):115–121PubMed Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ (2006) Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 10(3):115–121PubMed
11.
go back to reference Gerlini G, Di Gennaro P, Borgognoni L (2012) Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1(9):1655–1657PubMedCentralPubMedCrossRef Gerlini G, Di Gennaro P, Borgognoni L (2012) Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1(9):1655–1657PubMedCentralPubMedCrossRef
12.
go back to reference Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L (2013) Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 30(1):37–45PubMedCrossRef Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L (2013) Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 30(1):37–45PubMedCrossRef
13.
go back to reference Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132(11):1353–1357PubMedCrossRef Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R (1996) Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 132(11):1353–1357PubMedCrossRef
14.
go back to reference Gyorki DE, Yuan J, Mu Z et al (2013) Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 20(9):3106–3111PubMedCrossRef Gyorki DE, Yuan J, Mu Z et al (2013) Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma. Ann Surg Oncol 20(9):3106–3111PubMedCrossRef
15.
go back to reference Heller R, Jaroszeski MJ, Reintgen DS et al (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83(1):148–157PubMedCrossRef Heller R, Jaroszeski MJ, Reintgen DS et al (1998) Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 83(1):148–157PubMedCrossRef
16.
go back to reference Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R (2000) In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10(6):577–583PubMedCrossRef Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R (2000) In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 10(6):577–583PubMedCrossRef
17.
18.
go back to reference Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19(5):275–282PubMedCrossRef Kalialis LV, Drzewiecki KT, Klyver H (2009) Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res 19(5):275–282PubMedCrossRef
19.
go back to reference Kis E, Oláh J, Ócsai H, Baltas E, Gyulai R, Kemény L, Horvath AR (2011) Electrochemotherapy of cutaneous metastases of melanoma––a case series study and systematic review of the evidence. Dermatol Surg 37(6):816–824PubMed Kis E, Oláh J, Ócsai H, Baltas E, Gyulai R, Kemény L, Horvath AR (2011) Electrochemotherapy of cutaneous metastases of melanoma––a case series study and systematic review of the evidence. Dermatol Surg 37(6):816–824PubMed
20.
go back to reference Kroon BB, Noorda EM, Vrouenraets BC, van Slooten GW, Nieweg OE (2008) Isolated limb perfusion for melanoma. Surg Oncol Clin N Am 17(4):785–794 (viii–ix)PubMedCrossRef Kroon BB, Noorda EM, Vrouenraets BC, van Slooten GW, Nieweg OE (2008) Isolated limb perfusion for melanoma. Surg Oncol Clin N Am 17(4):785–794 (viii–ix)PubMedCrossRef
21.
23.
go back to reference Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39(1):4–16PubMedCrossRef Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39(1):4–16PubMedCrossRef
24.
go back to reference Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, Jarm T (2013) Tumor size and effectiveness of electrochemotherapy. Radiol Oncol 47(1):32–41PubMedCentralPubMedCrossRef Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, Jarm T (2013) Tumor size and effectiveness of electrochemotherapy. Radiol Oncol 47(1):32–41PubMedCentralPubMedCrossRef
25.
go back to reference Marty MSG, Garbay JR, Gehl J et al (2006) Electrochemotherapy––an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4:3–13CrossRef Marty MSG, Garbay JR, Gehl J et al (2006) Electrochemotherapy––an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4:3–13CrossRef
26.
go back to reference Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, Kotaka M, Ruedl C (2010) Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol 184(9):4625–4629PubMedCrossRef Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, Kotaka M, Ruedl C (2010) Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8+ T cell-derived licensing factor for dendritic cell activation. J Immunol 184(9):4625–4629PubMedCrossRef
27.
go back to reference Mir LM, Glass LF, Sersa G et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77(12):2336–2342PubMedCentralPubMedCrossRef Mir LM, Glass LF, Sersa G et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77(12):2336–2342PubMedCentralPubMedCrossRef
28.
go back to reference Mir LM, Orlowski S, Belehradek J Jr, Paoletti C (1991) Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27(1):68–72PubMedCrossRef Mir LM, Orlowski S, Belehradek J Jr, Paoletti C (1991) Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27(1):68–72PubMedCrossRef
29.
go back to reference Mir LM, Orlowski S, Poddevin B, Belehradek J Jr (1992) Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur Cytokine Netw 3(3):331–334PubMed Mir LM, Orlowski S, Poddevin B, Belehradek J Jr (1992) Electrochemotherapy tumor treatment is improved by interleukin-2 stimulation of the host’s defenses. Eur Cytokine Netw 3(3):331–334PubMed
30.
go back to reference Mir LM, Roth C, Orlowski S et al (1992) Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. CR Acad Sci III 314(12):539–544 Mir LM, Roth C, Orlowski S et al (1992) Potentiation of the antitumoral effect of electrochemotherapy by immunotherapy with allogeneic cells producing interleukin 2. CR Acad Sci III 314(12):539–544
31.
go back to reference Möller MG, Salwa S, Soden DM, O’Sullivan GC (2009) Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 9(11):1611–1630PubMedCrossRef Möller MG, Salwa S, Soden DM, O’Sullivan GC (2009) Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 9(11):1611–1630PubMedCrossRef
32.
go back to reference Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931PubMedCentralPubMedCrossRef Postow MA, Callahan MK, Barker CA et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925–931PubMedCentralPubMedCrossRef
33.
go back to reference Quaglino P, Mortera C, Osella-Abate S et al (2008) Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 15(8):2215–2222PubMedCrossRef Quaglino P, Mortera C, Osella-Abate S et al (2008) Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 15(8):2215–2222PubMedCrossRef
34.
go back to reference Quaglino P, Osella-Abate S, Marenco F, Nardò T, Gado C, Novelli M, Savoia P, Bernengo MG (2011) FoxP3 expression on melanoma cells is related to early visceral spreading in melanoma patients treated by electrochemotherapy. Pigment Cell Melanoma Res 24(4):734–736PubMedCrossRef Quaglino P, Osella-Abate S, Marenco F, Nardò T, Gado C, Novelli M, Savoia P, Bernengo MG (2011) FoxP3 expression on melanoma cells is related to early visceral spreading in melanoma patients treated by electrochemotherapy. Pigment Cell Melanoma Res 24(4):734–736PubMedCrossRef
35.
go back to reference Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Peterson B, Seigler H, Pruitt SK, Tyler DS (2011) Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 213(2):306–316PubMedCentralPubMedCrossRef Raymond AK, Beasley GM, Broadwater G, Augustine CK, Padussis JC, Turley R, Peterson B, Seigler H, Pruitt SK, Tyler DS (2011) Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 213(2):306–316PubMedCentralPubMedCrossRef
36.
go back to reference Reinhold U (2011) Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies. Anticancer Drugs 22(8):711–718PubMedCrossRef Reinhold U (2011) Electrochemotherapy for primary skin cancer and skin metastasis related to other malignancies. Anticancer Drugs 22(8):711–718PubMedCrossRef
38.
go back to reference Rols MP, Bachaud JM, Giraud P, Chevreau C, Roché H, Teissié J (2000) Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 10(5):468–474PubMedCrossRef Rols MP, Bachaud JM, Giraud P, Chevreau C, Roché H, Teissié J (2000) Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 10(5):468–474PubMedCrossRef
39.
go back to reference Roux S, Bernat C, Al-Sakere B et al (2008) Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57(9):1291–1300PubMedCrossRef Roux S, Bernat C, Al-Sakere B et al (2008) Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57(9):1291–1300PubMedCrossRef
40.
go back to reference Rudolf Z, Stabuc B, Cemazr M et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29:229–235 Rudolf Z, Stabuc B, Cemazr M et al (1995) Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 29:229–235
41.
go back to reference Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z (2000) Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 10(4):381–385PubMedCrossRef Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z (2000) Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 10(4):381–385PubMedCrossRef
42.
go back to reference Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D (1997) Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett 116(1):85–92PubMedCrossRef Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D (1997) Anti-tumor effectiveness of electrochemotherapy with bleomycin is increased by TNF-alpha on SA-1 tumors in mice. Cancer Lett 116(1):85–92PubMedCrossRef
43.
go back to reference Sersa G, Cemazar M, Rudolf Z (2003) Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther 1:133–142 Sersa G, Cemazar M, Rudolf Z (2003) Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther 1:133–142
44.
go back to reference Sersa G, Miklavcic D, Cemazar M et al (1997) Electrochemothrapy with CDDP on LPB sarcoma: comparison of the antitumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochem Bioenerg 43:279–283CrossRef Sersa G, Miklavcic D, Cemazar M et al (1997) Electrochemothrapy with CDDP on LPB sarcoma: comparison of the antitumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochem Bioenerg 43:279–283CrossRef
45.
go back to reference Schadendorf D, Vaubel J, Livingstone E, Zimmer L (2012) Advances and perspectives in immunotherapy of melanoma. Ann Oncol 23(Suppl 10):x104–x108PubMedCrossRef Schadendorf D, Vaubel J, Livingstone E, Zimmer L (2012) Advances and perspectives in immunotherapy of melanoma. Ann Oncol 23(Suppl 10):x104–x108PubMedCrossRef
46.
go back to reference Sojka DK, Donepudi M, Bluestone JA, Mokyr MB (2000) Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 164(12):6230–6236PubMedCrossRef Sojka DK, Donepudi M, Bluestone JA, Mokyr MB (2000) Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J Immunol 164(12):6230–6236PubMedCrossRef
47.
go back to reference Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109(3):270–274PubMedCrossRef Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F (2014) Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol 109(3):270–274PubMedCrossRef
48.
go back to reference Spagnolo F, Queirolo P (2012) Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 304(3):177–184PubMedCrossRef Spagnolo F, Queirolo P (2012) Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res 304(3):177–184PubMedCrossRef
49.
go back to reference Testori A, Faries MB, Thompson JF et al (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104(4):391–396PubMedCrossRef Testori A, Faries MB, Thompson JF et al (2011) Local and intralesional therapy of in-transit melanoma metastases. J Surg Oncol 104(4):391–396PubMedCrossRef
50.
go back to reference Testori A, Tosti G, Martinoli C et al (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23(6):651–661PubMedCrossRef Testori A, Tosti G, Martinoli C et al (2010) Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 23(6):651–661PubMedCrossRef
51.
go back to reference Triozzi PL, Tuthill RJ, Borden E (2011) Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy 3(5):653–671PubMedCrossRef Triozzi PL, Tuthill RJ, Borden E (2011) Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy 3(5):653–671PubMedCrossRef
52.
go back to reference Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 1291:1–13PubMedCentralPubMedCrossRef Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, O’Day SJ, Hoos A, Humphrey R, Berman DM, Lonberg N, Korman AJ (2013) Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann NY Acad Sci 1291:1–13PubMedCentralPubMedCrossRef
53.
go back to reference Crisan M, Crisan D, Sannino G, Lupsor M, Badea R, Amzica F (2013) Ultrasonographic staging of cutaneous malignant tumors: an ultrasonographic depth index. Arch Dermatol Res 305:305–313PubMedCrossRef Crisan M, Crisan D, Sannino G, Lupsor M, Badea R, Amzica F (2013) Ultrasonographic staging of cutaneous malignant tumors: an ultrasonographic depth index. Arch Dermatol Res 305:305–313PubMedCrossRef
55.
go back to reference Ruksha T, Aksenenko M, Papadopoulos V (2012) Role of translocator protein in melanoma growth and progression. Arch Dermatol Res 304:839–845PubMedCrossRef Ruksha T, Aksenenko M, Papadopoulos V (2012) Role of translocator protein in melanoma growth and progression. Arch Dermatol Res 304:839–845PubMedCrossRef
Metadata
Title
Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy
Authors
Paola Queirolo
Francesco Marincola
Francesco Spagnolo
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Archives of Dermatological Research / Issue 6/2014
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-014-1462-x

Other articles of this Issue 6/2014

Archives of Dermatological Research 6/2014 Go to the issue